Curated News
By: NewsRamp Editorial Staff
October 14, 2026
Scinai Immunotherapeutics Secures $4M in Private Placement to Fuel CDMO and Immunotherapy Growth
TLDR
- Scinai Immunotherapeutics raised $4 million to expand its CDMO platform and advance its immunotherapy pipeline, potentially gaining a competitive edge.
- Scinai Immunotherapeutics secured $4 million through a private placement of 2,458,334 ADSs and warrants at $1.20 per ADS, with closing expected by Oct. 15, 2026.
- Scinai Immunotherapeutics' $4 million funding will advance immunotherapy development and expand CDMO services, potentially leading to better treatments and improved health outcomes.
- Scinai Immunotherapeutics is raising $4 million by selling stock and warrants at $1.20 each to fund its CDMO and immunotherapy work.
Impact - Why it Matters
This funding provides Scinai with critical capital to scale its CDMO operations and advance its immunotherapy pipeline, potentially accelerating revenue generation and therapeutic development. For investors, it signals confidence from an existing institutional investor and could enhance the company's growth prospects. Moreover, the expansion of CDMO services supports the broader biotech ecosystem by offering development and manufacturing capabilities, while the immunotherapy advancements may lead to novel treatments licensed from prestigious institutions like the Max Planck Society.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company with a dual focus on contract development and manufacturing (CDMO) and immunotherapy development, has announced securities purchase and warrant inducement agreements with an existing institutional investor. The transactions are expected to generate approximately $4 million in aggregate gross proceeds. The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, along with warrants to purchase up to 3,687,501 additional ADSs, priced at a combined $1.20 per ADS and accompanying warrants. Additionally, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The deal is anticipated to close on or about Oct. 15, 2026, subject to customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transactions.
Scinai plans to use the net proceeds, together with existing cash resources, to expand its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms. The company’s immunotherapy pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services through facilities in Jerusalem and Yavne, Israel. For more details, see the full press release at https://ibn.fm/eUtYO. The latest updates on SCNI can be found in the company’s newsroom at https://ibn.fm/SCNI.
MissionIR is a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies. It is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. With a broad reach and seasoned team, MIR connects clients with investors, influencers, consumers, journalists, and the public. For more information, visit www.MissionIR.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Secures $4M in Private Placement to Fuel CDMO and Immunotherapy Growth
